"We are delighted that these positive Phase 3 data for OCREVUS administered subcutaneously with ENHANZE opens up the potential for people living with multiple sclerosis to receive their treatment in just 10 minutes, twice a year," said Dr. Helen Torley
https://www.prnewswire.com/news-rele...301876188.html
https://www.prnewswire.com/news-rele...301876188.html
Comment